On Monday, Chinese President Xi Jinping presided over a meeting with Alibaba co-founder Jack Ma and other prominent ...

China is not ready for war, according to a contentious report from a US think tank, which claims the main motivation for the ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Ahead of the final Merseyside derby at Goodison Park, reminisce over one of the most memorable clashes between Everton and ...

Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI inhibitor ...

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

Novartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront ...

Anthos was founded by private equity firm Blackstone's Life Sciences business and by Novartis in 2019 to develop, manufacture ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

Today, the rejuvenation of Northeast China stands as a cornerstone strategy endorsed by the Communist Party of China Central ...

WASHINGTON: US President Donald Trump said Tuesday (Feb 4) he was not in a hurry to speak with his Chinese counterpart Xi Jinping, despite expectations that they would hold talks after announcing ...